TNFSF4 and histiocytic sarcoma: By simultaneously inhibiting innate immunity (TNF-α) and adaptive immunity (OX40L-mediated T-cell and B-cell interactions), it may more comprehensively intervene in the complex pathophysiology of HS, potentially achieving greater efficacy than existing single-target therapies such as adalimumab.